MNPR-202 is an early-stage camsirubicin analog that retains the same potentially non-cardiotoxic backbone as camsirubicin but is modified at other positions with the aim to increase potency and circumvent drug resistance pathways in cancer cells. MNPR-202 is being developed to explore various cancer indications outside of the scope of camsirubicin.